

FY2025 R&D Tax Incentive Received & EndPoints Capital Loan Repayment

Melbourne, Australia, 18 November 2025: Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX:RHY), a transformative, predictive cancer diagnostics technology company, advises it has received its Research and Development Tax Incentive ('RDTI') of \$1.571m as foreshadowed and repaid \$1m in non-dilutive funding from Endpoints Capital ('EndPoints').

As previously announced, the Company had drawn down \$1m of the EndPoints funding as at 30 June 2025, secured and payable via the FY25 RDTI rebate. In accordance with the non-dilutive funding arrangement, the RDTI refund was processed to EndPoints, with net proceeds of \$0.515m disbursed to Rhythm.

The Australian Government RDTI program provides eligible companies with a rebate against research and development related expenditure by way of refundable tax offset. Rhythm will continue to participate in the Government's R&D incentive program and will again submit an annual R&D claim lodgement for the 2026 financial year.

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet relevant regulatory standards.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

Australian Registered Address
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

Directors

Gavin Fox-Smith
Sue MacLeman
David Atkins

Non-Executive Chairman
Non-Executive Director
CEO & Managing Director

www.rhythmbio.com

T +61 3 8256 2880
E info@rhythmbio.com



including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genotype.com.